Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.56 |
| ▸ | DRD3 | P35462 | 4/20 | 0.56 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1682787 | 1.00 | DRD2 (0.56) | DRD2DRD3PLAUHTR6ANPEP | |
| SCHEMBL7554445 | 0.84 | DRD2 (0.63) | DRD2DRD3PLAUHTR6ANPEP | |
| SCHEMBL4099869 | 0.82 | TBXA2R (0.36) | DRD2DRD3TBXA2R | |
| SCHEMBL2486276 | 0.80 | DRD2 (0.48) | DRD2DRD3PLAUHTR6TBXA2R | |
| SCHEMBL526993 | 0.80 | TBXA2R (0.55) | DRD2DRD3PLAUHTR6TBXA2R | |
| Bromide SCHEMBL2482900 | 0.79 | DRD2 (0.47) | DRD2DRD3PLAUHTR6TBXA2R | |
| Hydrochloric Acid SCHEMBL9255960 | 0.75 | DRD2 (0.51) | DRD2DRD3PLAUHTR6TBXA2R | |
| SCHEMBL9070606 | 0.74 | BCL2L1 (0.44) | TBXA2RALDH1A1 | |
| SCHEMBL11355027 | 0.74 | BCL2L1 (0.48) | TBXA2RALDH1A1KDM4E | |
| SCHEMBL15078827 | 0.74 | ALDH1A1 (0.55) | DRD2DRD3HTR6TBXA2RALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180177760-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N-SUBSTITUTED-2-AMINOTETRALINS, AND RELATED DOSAGE FORMS | SPRIASO LLC (US) | 2018-06-28 | — | — | US | disclosed |
| US-9956201-B2 | Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms | SPRIASO LLC (US) | 2018-05-01 | — | — | US | disclosed |
| WO-2016014242-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N-SUBSTITUTED-2-AMINOTETRALINS, DOSAGE FORMS, AND RELATED METHODS | SPRIASO LLC (US) | 2016-01-28 | — | — | WO | disclosed |
| US-20160015684-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N- SUBSTITUTED-2-AMINOTETRALINS, DOSAGE FORMS, AND RELATED METHODS | SPRIASO LLC | 2016-01-21 | — | — | US | disclosed |
| US-20160016887-A1 | Methods of treating a subject using bioreversible derivatives of hydroxy n-substituted-2-aminotetralins | SPRIASO LLC | 2016-01-21 | — | — | US | disclosed |
| US-8513438-B2 | Process for the preparation of (6S)-(-)-5,6,7,8-tetrahydro-6-[propyl-(2-thienyl)ethyl]amino-1-naphthol (Rotigotine) | INTERQUIM, S.A. (ES) | 2013-08-20 | — | — | US | disclosed |
| US-20110306776-A1 | PROCESS FOR THE PREPARATION OF (6S)-(-)-5,6,7,8-TETRAHYDRO-6-[PROPYL-(2-THIENYL)ETHYL]AMINO-1-NAPHTHOL (ROTIGOTINE) | INTERQUIM, S.A. (ES) | 2011-12-15 | — | — | US | disclosed |
| EP-2376470-A1 | PROCESS FOR THE PREPARATION OF (6S)-(-)-5,6,7,8-TETRAHYDRO-6-ÝPROPYL-(2-THIENYL)ETHYL¨AMINO-1-NAPHTHOL (ROTIGOTINE) | Interquim, S.A (ES) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010066755-A1 | PROCESS FOR THE PREPARATION OF (6S)-(-)-5,6,7,8-TETRAHYDRO-6-[PROPYL-(2-THIENYL)ETHYL]AMINO-1-NAPHTHOL (ROTIGOTINE) | INTERQUIM, S.A. (ES) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016887-A1 | Methods of treating a subject using bioreversible derivatives of hydroxy n-substituted-2-aminotetralins | SLC7A1, CYP2D6, SLC19A1 | DRD2 1496/4885DRD3 1430/4885PLAU 1137/4885 |
| US-20160015684-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N- SUBSTITUTED-2-AMINOTETRALINS, DOSAGE FORMS, AND RELATED METHODS | SLC7A1, CYP2D6, CYP3A7 | DRD2 1602/4885DRD3 1564/4885PLAU 1810/4885 |
| US-20180177760-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N-SUBSTITUTED-2-AMINOTETRALINS, AND RELATED DOSAGE FORMS | SLC7A1, CYP2D6, CYP3A7 | DRD2 1234/4885DRD3 1281/4885PLAU 1748/4885 |
| US-20110306776-A1 | PROCESS FOR THE PREPARATION OF (6S)-(-)-5,6,7,8-TETRAHYDRO-6-[PROPYL-(2-THIENYL)ETHYL]AMINO-1-NAPHTHOL (ROTIGOTINE) | NAT1, COMT, PARK7 | DRD2 228/4885DRD3 161/4885PLAU 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.